Smoking, nicotine and psychiatric disorders: Evidence for therapeutic role, controversies and implications for future research

Medical Hypotheses

Volumn 52, Issue 2, 1999, Pages 101-109

  Dursun, S M ^a   Kutcher, S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NEUROTRANSMITTER; NICOTINE; NICOTINIC RECEPTOR; NORADRENALIN; SEROTONIN;

ANXIETY; ARTICLE; DEPRESSION; DRUG DEPENDENCE; DRUG MISUSE; GILLES DE LA TOURETTE SYNDROME; MEDICAL ETHICS; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; SMOKING; TOBACCO;

EID: 0033080832     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1997.0623     Document Type: Article

References (78)

1. Pool W. E., Godin C. S., Crooks P. A. Nicotine racemization during cigarette smoking. The Toxicologist 1985; 5: 232.
2. Jaffe J. H. Drug addiction and drugs abuse. In: Gilman A. C., Goodman L. S., Rail T. W., Murad F., eds. The Pharmacological Basis of Therapeutics. New York: Macmillan, 1985: 532-581.
3. Fibiger H. C. The organization of some projections of cholinergic neurons of the manolian forebrain. Brain Res Brain Res Rev 1982; 4: 327-388.
4. Clarke P. B. S. Nicotine and smoking: A perspective from animal studies. Psychopharmacology 1987; 92: 135-143.
5. Plowchalk D. R., deBethizy D. Interspecies scaling of nicotine concentrations in the brain. In: Lippiello P. M., Collins A. C., Gray J. A., Robinson J. H., eds. The Biology of Nicotine: Current Research Issues. New York: Raven Press, 1992: 55-70.
6. Armitage A. K., Hall G. H., Morrison C. F. Pharmacological basis for smoking habit. Nature 1968; 217: 331-334.
7. Remond A., Martinerie J., Baillon J. F. Nicotine intake compared with other psychophysiological situations through quantitative EEG analysis. In: Remond A., Izard C., eds. Electrophysiological Effects of Nicotine. Amsterdam: Elsevier Biomedical Press, 1979: 61-87.
8. Balfour D. J. K. The effects of nicotine on brain neurotransmitter systems. Pharmacol Ther 1982; 16: 269-282.
9. Hall G. H. Pharmacological responses to the intracerebral administration of nicotine. Pharmacol Ther 1982; 15: 223-238.
10. Fuxe K., Hokfelt T., Ungerstedt U. Morphological and functional aspects of central monoamine neurons. Int Rev Neurobiol 1970; 13: 93-126.
11. 3H-acetylcholine on catecholamine and serotonin axons in brain. J Neurochem 1984; 42: 1495-1498.
12. Westfall T., Grant H., Perry H. Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. Gen Pharmacol 1983; 14: 321-325.
13. Benwell M. E. M., Balfour D. J. K. Effects of nicotine and its withdrawal on plasma corticosterone and brain 5-hydroxy-indoles. Psychopharmacology 1979; 63: 7-11.
14. Benwell M. E. M., Balfour D. J. K. Effects of nicotine administration on the uptake and biosynthesis of 5-HT in rat brain synaptosomes. Eur J Pharmacol 1982; 84: 71-77.
15. Balfour D. J. K. Influence of nicotine on the release of monoamines in the brain. Prog Brain Res 1989; 79: 165-172.
16. Balfour D. J. K., Khuller A. K., Longden A. The effects of nicotine plasma corticosterone and brain amines in stressed and unstressed rats. Pharmacol Biochem Behav 1975; 3: 179-184.
17. Balfour D. J. K., Graham C. A., Vale A. L. Studies on the possible role of brain 5-HT systems and adrenocortical activity in behavioural responses to nicotine and diazepam in an elevated x-maze. Psychopharmacology 1986; 90: 528-532.
18. Svensson T., Enberg G. Effect of nicotine on single cell activity in the noradrenergic nucleus coeruleus. Acta Physiol Scand 1980; S479: 31-34.
19. Morgan W. W., Pfeil K. A. Mecamylamine blockade of nicotine enhanced noradrenaline turnover in rat brain. Life Sci 1979; 24: 417-420.
20. Kirch D. G., Gerhardt G. A., Shelton R. C., Freedman R., Wyatt R. J. Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain. Clin Neuropharmacol 1987; 10: 376-383.
21. Cooper J. R., Bloom F. E., Roth R. H. The Biochemical Basis of Neuropharmacology, 3rd Edn. New York: Oxford University Press, 1978.
22. Andersson K., Fuxe K., Agnati L. F., Eneroth P. Effects of acute central and peripheral administration of nicotine on ascending dopamine pathways in the male rat brain. Evidence for nicotine induced increases of dopamine turnover in various telencephalic dopamine nerve terminal systems. Med Biol 1981; 59: 170-176.
23. Andersson K., Fuxe K., Agnati L. F. Effects of single injections of nicotine on the ascending dopamine pathways in the rat. Acta Physiol Scand 1981; 112: 345-347.
24. Ahtee L., Kaakkola S. Effect of mecamylamine on the fate of dopamine in striatal and mesolimbic areas of rat brain: Interaction with morphine and haloperidol. Br J Pharmacol 1978; 62: 213-218.
25. Clarke P. B. S., Homer D. W., Pert A., Skirboll L. R. Electrophysiological actions of nicotine on substantia nigra single units. Br J Pharmacol 1985; 85: 827-835.
26. Imperato A., Mulas A., Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 1986; 132: 337-338.
27. Clarke P. B. S., Fu D. S., Jakubovic A., Fibiger H. C. Evidence that mesolimbic dopamine activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther 1988; 246: 701-708.
28. Stolerman I. P. Behavioural pharmacology of nicotine in animals. In: Wonnacott S., Russell M. A. H., Stolerman I. P., eds. Nicotine Psychopharmacology. Oxford: Oxford University Press, 1990: 278-306.
29. Goldberg S. R., Spealman R. D. Suppression of behaviour by intravenous injections of nicotine or by electric shock in squirrel monkeys: Effects of chlordiazepoxide and mecamylamine. J Pharmacol Exp Ther 1983; 224(2): 334-340.
30. Glassman A. H. Cigarette smoking: Implications for psychiatric illness. Am J Psychiatry 1993; 150: 546-553.
31. George T. P., Ziedonis D. M. Schizophrenia and nicotine use: A report of a pilot smoking cessation program and a review of neurobiological and clinical issues. Schizophr Bull 1997: in press.
32. Hughes J. R. Tobacco withdrawal in self-quitters. J Consult Clin Psychol 1992; 60: 689-697.
33. Jarvik M. E. Beneficial effects of nicotine. Br J Addict 1991; 86: 571-575.
34. Geoff D. C., Henderson D. C., Amico E. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatry 1992; 149: 1189-1194.
35. Ziedonis D. M., Kosten T. R., Glazer W. M., Frances R. J. Nicotine dependence and schizophrenia. Hosp Commun Psychiatry 1994; 45: 204-206.
36. Adler L. E., Hoffer L. J., Griffith J., Waldo M. C., Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 1992; 32: 607-616.
37. Klein C., Andersen B. On the influence of smoking upon smooth pursuit eye movements of schizophrenics and normal controls. J Psychophysiol 1991; 5: 361-369.
38. Vinogradova O. S. Functional organization of the limbic system in the process of registration of information: Facts and hypothesis. In: Isaacson R. L., Pribram K. H., eds. The Hippocampus. 2: Neurophysiology and Behaviour. New York: Plenum, 1975: 3-70.
39. Goff W. R., Williamson P. D., VanGilder J. C., Allison T., Fisher T. C. Neural origins of long latency evoked potentials recorded from the depth of and from the cortical surface of the brain in man. Prog Clin Neurophysiol 1980; 7: 126-145.
40. Leonard S., Adams C., Breese C. R. et al. Nicotine receptor function in schizophrenia. Schizophr Bull 1992; 22(3): 431-444.
41. Luntz-Leybman V., Bickford P., Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res Rev 1992; 587: 130-136.
42. Ségu̧éla P., Wadiche J., Dineley-Millar K., Dani J. A., Patrick J. W. Molecular cloning, functional properties, and distribution of rat brain. 7: A nicotine cation channel highly permeable to calcium. J Neurosci 1993; 13: 596-604.
43. Freedman R., Hall M., Adler L. E., Leodard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995; 38: 22-33.
44. Chini B., Raimond E., Elgoyhen A. B., Moralli D., Balzaretti M., Heinemann S. Molecular cloning and chromosomal localization of the human 7-nicotinic receptor subunit gene (CHRNA7). Genomics 1994; 19: 379-381.
45. Coon H., Plaetke R., Holik J. et al. Use of a neurophysiological trait in linkage analysis of schizophrenia. Biol Psychiatry 1993; 34: 277-289.
46. Waal-Manning H. J., de Hamel F. A. Smoking habit and psychometric scores: A community study. NZ Med J 1978; 88: 188-191.
47. Pomerleau O., Adkins D., Pertschuk M. Predictors of outcome and recidivism in smoking cessation treatment. Addict Behav 1978; 3: 65-70.
48. Glassman A. H., Stetner F., Walsh B. T. et al. Heavy smokers, smoking cessation and clonidine. Results of a double-blind, randomized trial. J Am Med Assoc 1988; 259: 2863-2866.
49. Breslau N., Kilbey M. M., Andreski P. Nicotine dependence and major depression. New evidence from a prospective investigation. Arch Gen Psychiatry 1993; 50: 31-35.
50. Covey L. S., Glassman A. H., Stetner F. Depression and depressive symptoms in smoking cessation. Compr Psychiatry 1990; 31: 350-354.
51. Hall S. M., Munoz R., Reus V. Depression and smoking treatment: A clinical trial of an affect regulation treatment. NIDA Res Monogr 1992; 119: 326.
52. West R. J., Hajek P., Belcher M. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med 1989; 19: 981-985.
53. Breslau N., Kilbey M. M., Andreski P. Nicotine dependence and major depression, and anxiety in young adults. Arch Gen Psychiatry 1991; 48: 1069-1074.
54. Zimmerman M., Coryell W. H., Black D. W. Cigarette smoking and psychiatric illness. In: CME Syllabus and Scientific Proceedings in Summary Form, 144th Annual Meeting of the American Psychiatric Association. Washington, DC: APA, 1991.
55. Pohl R. B., Yeragani V. K., Balon R., Lycaki H., Kareus R. M. Smoking in panic disorder patients. In: CME Syllabus and Scientific Proceedings in Summary Form, 145th Annual Meeting of the American Psychiatric Association. Washington, DC: APA, 1992.
56. Covey L. S., Hughes D., Glassman A. H., Blazer D. G., George L. K. Major depression, other psychiatric disorders, and cigarette smoking. In: Proceedings of the 25th Annual Meeting of the Society for Epidemiological Research, Baltimore, 1992.
57. Pomerleau O. F. Nicotine as a psychoactive drug: Anxiety and pain reduction. Psychopharmacol Bull 1986; 22: 865-869.
58. Brioni J. K., O'Neill A. B., Kim D. J. B., Decker M. W. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur J Pharmacol 1993; 238: 1-8.
59. Robertson M. M. The Gilles de la Tourette Syndrome: The current status. Br J Psychiatry 1989; 154: 147-169.
60. Handley S. L., Dursun S. M. Serotonin and Tourette's syndrome: Movements such as head-shakes and wet-dog shakes may model human tics. Adv Biosci 1992; 85: 235-253.
61. McConville B. J., Fogelson M. H., Klykylo W. M., Manderscheid P. Z., Parder K. W., Sanberg P. R. Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder. Am J Psychiatry 1991; 148: 793-794.
62. Silver A. A., Sanberg P. R. Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome. Lancet 1993: 182.
63. Reveley M. A., Bird R., Stirton R. F., Dursun S. M. Microstructural analysis of the symptoms of Tourette's syndrome and the effects of a trial use of transdermal nicotine patch. J Psychopharmacol Suppl 1994; 117: A30.
64. Dursun S. M., Bird R., Reveley M. A. Differential effects of transdermal nicotine patch on the symptoms of Tourette's syndrome. Br J Clin Pharmacol 1995; 39: 100P-101P.
65. Dursun S. M., Reveley M. A., Bird R., Stirton R. F. Long lasting improvement of Tourette's syndrome with transdermal nicotine. Lancet 1994; 344: 1577.
66. Manderscheid P. Z., Sanberg P. R., Noerman A. B. et al. Nicotine markedly potentiates neuroleptic induced catalepsy. Soc Neurosci Abstr 1988; 14: 1257.
67. Sanberg P. R., McConville B. J., Fogelson H. M. et al. Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette's syndrome. Biomed Pharmacother 1989; 43: 19-23.
68. Emerich D. F., Zanol M. D., Norman A. B., McConville B. J., Sanberg P R. Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity. Pharmacol Biochem Behav 1991; 38: 875-880.
69. McConville B. H., Sanberg P. R., Fogelson M. H. et al. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tics severity and frequency in Tourette's disorder. Biol Psychiatry 1992; 31: 832-840.
70. Richelson E. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 1984; 45: 331-336.
71. Gerlach J., Reisby N., Randup A. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia 1974; 34: 21-35.
72. Sethy V. M., Vanwoert M. H. Modification of striatal acetylcholine concentration by dopamine receptor agonists and antagonists. Res Commun Chem Pathol Pharmacol 1974; 8: 13-28.
73. Bannet J., Belmaker R. H., eds. New Directions in Tardive Dyskinesia Research. Karger: Basel, 1983.
74. Dursun S. M., Reveley M. A. The efficacy of a dose-escalated application of transdermal nicotine plus sulpiride in Tourette's syndrome. Eur Psychiatry 1996; 11: 204-206.
75. Dursun S. M., Reveley M. A. Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome. Psychiatry Med 1997: in press.
76. 2-dopamine receptor density. Biochem Biophys Res Commun 1989; 159: 48-52.
77. Dursun S. M., Burke J. G., Reveley M. A. Buspirone treatment of Tourette's syndrome. Lancet 1995; 345: 1366-1367.
78. 1a receptor agonists in the mouse. Br J Pharmacol 1993; 109: 1046-1052.